Secukinumab attenuates reactive astrogliosis via IL-17RA/(C/EBPβ)/SIRT1 pathway in a rat model of germinal matrix hemorrhage.
Sheng-Peng LiuLei HuangJerry FloresYan DingPeng LiJun PengGang ZuoJohn H ZhangJun LuJi-Ping TangPublished in: CNS neuroscience & therapeutics (2019)
Secukinumab attenuated reactive astrogliosis and reduced neurological deficits after GMH, partly by regulating IL-17RA/(C/EBPβ)/SIRT1 pathways. Secukinumab may provide a promising therapeutic strategy for GMH patients.
Keyphrases
- ankylosing spondylitis
- rheumatoid arthritis
- end stage renal disease
- disease activity
- chronic kidney disease
- oxidative stress
- ejection fraction
- newly diagnosed
- traumatic brain injury
- ischemia reperfusion injury
- prognostic factors
- patient reported outcomes
- systemic lupus erythematosus
- brain injury
- systemic sclerosis
- blood brain barrier